HomeCompareBRCTF vs KMB

BRCTF vs KMB: Dividend Comparison 2026

BRCTF yields 6.06% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $16.0K in total portfolio value
10 years
BRCTF
BRCTF
● Live price
6.06%
Share price
$33.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.8K
Annual income
$891.01
Full BRCTF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — BRCTF vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRCTFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRCTF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRCTF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCTF
Annual income on $10K today (after 15% tax)
$514.84/yr
After 10yr DRIP, annual income (after tax)
$757.36/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KMB beats the other by $3,672.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCTF + KMB for your $10,000?

BRCTF: 50%KMB: 50%
100% KMB50/50100% BRCTF
Portfolio after 10yr
$37.9K
Annual income
$3,051.16/yr
Blended yield
8.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

BRCTF
No analyst data
Altman Z
30.8
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCTF buys
0
KMB buys
0
No recent congressional trades found for BRCTF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRCTFKMB
Forward yield6.06%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$29.8K$45.9K
Annual income after 10y$891.01$5,211.33
Total dividends collected$7.5K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BRCTF vs KMB ($10,000, DRIP)

YearBRCTF PortfolioBRCTF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,306$605.69$11,314$613.68$8.00KMB
2$12,737$639.98$12,865$759.19$128.00KMB
3$14,303$673.84$14,709$943.96$406.00KMB
4$16,011$707.15$16,919$1,180.17$908.00KMB
5$17,871$739.83$19,588$1,484.33$1.7KKMB
6$19,894$771.78$22,838$1,879.06$2.9KKMB
7$22,090$802.93$26,832$2,395.60$4.7KKMB
8$24,469$833.21$31,788$3,077.63$7.3KKMB
9$27,045$862.59$38,000$3,986.82$11.0KKMB
10$29,829$891.01$45,872$5,211.33$16.0KKMB

BRCTF vs KMB: Complete Analysis 2026

BRCTFStock

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.

Full BRCTF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this BRCTF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCTF vs SCHDBRCTF vs JEPIBRCTF vs OBRCTF vs KOBRCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.